“A comprehensive exploration of the condition and the cutting-edge therapeutic options being developed for the management of cystic fibrosis . . . A quality book on cystic fibrosis management.”—From the Foreword by Dr. Dhruv Galgotia, CEO, Galgotias University, Greater Noida, IndiaBringing together current research, therapeutic advances, and clinical perspectives, the volume offers a cohesive understanding of cystic fibrosis (CF) and the evolving strategies used to manage it. By bridging fundamental science with applied pharmaceutical innovation, this book underscores a shift toward more targeted, efficient, and patient-specific treatment strategies.The book begins with a clear overview of CF, outlining its genetic basis, clinical manifestations, and significant impact on patient health and quality of life. It then explores the underlying pathophysiology associated with CFTR mutations, emphasizing the disruptions in cellular processes that drive disease progression. Particular attention is given to microbial infections, which play a critical role in worsening symptoms, reinforcing the need for effective infection control and integrated care approaches. Building on this foundation, the volume highlights emerging and advanced therapeutic approaches. It examines the growing importance of gene therapy and personalized medicine, alongside innovations in drug delivery systems designed to enhance treatment precision and effectiveness. Technologies such as liposomes, lipid nanoparticles, and polymeric nanocarriers are presented as key enablers of targeted delivery.

Produktinformation

Utgivningsdatum2026-08-10
Mått178 x 254 x 24 mm
Vikt910 g
FormatInbunden
SpråkEngelska
Antal sidor386
FörlagApple Academic Press Inc.
ISBN9781779640406

Tillhör följande kategorier

Biomedicinsk teknik inom Medicin
Alternativ medicin och terapier inom Medicin

Bhupendra G. Prajapati, PhD, is a Professor of Pharmacy at Parul University, India, and Adjunct Professor at Silpakorn University, Thailand. With over two decades of experience in academia, research, and industry, he specializes in lipid-based and nano drug delivery systems. A recipient of several prestigious awards, he has published extensively, including many papers and edited books.Rishabha Malviya, PhD, is an Associate Professor in the School of Medical & Allied Sciences at Galgotias University, India. With research expertise in nanoformulations and targeted drug delivery, he has authored many papers, holds numerous patents, and has edited multiple books. He is a reviewer, editor, and editorial board member of more than 50 national and international journals..Sonali Sundram, PhD, is an Assistant Professor in the School of Medical & Allied Sciences at Galgotias University, India, focusing on neurodegeneration, nanoformulation, and clinical research. She has edited several books, holds multiple national and international patents, and has spoken at international conferences in Europe.Akshay Parihar, MPharm, is an Assistant Professor in the Faculty of Pharmaceutical Sciences, Institute of Chartered Financial Analysts of India University, India, and a doctoral researcher at Ganpat University, specializing in novel drug delivery systems for improved therapeutic outcomes in cystic fibrosis.

Foreword by Dhruv Galgotia Preface 1. Introduction to Cystic Fibrosis 2. Pathophysiological Aspects of Cystic Fibrosis 3. The Role of Microorganisms in Causing Cystic Fibrosis 4. Novel Therapeutic Approaches for Cystic Fibrosis 5. Cystic Fibrosis: Disease and Advanced Drug Delivery Systems 6. Lipid Nanoparticles in Treating Cystic Fibrosis 7. Regulations for Monitoring and Management of Cystic Fibrosis 8. Aerosol Antibiotics in Management of Cystic Fibrosis 9. Polymeric Nanoparticles in Treating Cystic Fibrosis 10. Medical Devices Used in Cystic Fibrosis 11. Anti-Inflammatory Agents Used in Cystic Fibrosis 12. Challenges for Development of Formulation in Cystic Fibrosis 13. Epigenetic Modifications in CFTR Regulation, Gene Expression and Its Impact on Cystic Fibrosis Development 14. Heart Failure in Cystic Fibrosis: Treatment and Prognosis 15. Diagnostic Tools for Cystic Fibrosis 16. Nanomedicine for Cystic Fibrosis